Acadia Pharmaceuticals (ACAD) Cash from Operations (2016 - 2025)
Historic Cash from Operations for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $74.3 million.
- Acadia Pharmaceuticals' Cash from Operations rose 1745.88% to $74.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year decrease of 186.41%. This contributed to the annual value of $157.7 million for FY2024, which is 84431.21% up from last year.
- Acadia Pharmaceuticals' Cash from Operations amounted to $74.3 million in Q3 2025, which was up 1745.88% from $64.0 million recorded in Q2 2025.
- Over the past 5 years, Acadia Pharmaceuticals' Cash from Operations peaked at $85.4 million during Q4 2023, and registered a low of -$76.3 million during Q1 2022.
- In the last 5 years, Acadia Pharmaceuticals' Cash from Operations had a median value of -$727000.0 in 2022 and averaged $4.9 million.
- Data for Acadia Pharmaceuticals' Cash from Operations shows a peak YoY increase of 45796.51% (in 2023) and a maximum YoY decrease of 800935.35% (in 2023) over the last 5 years.
- Quarter analysis of 5 years shows Acadia Pharmaceuticals' Cash from Operations stood at -$23.1 million in 2021, then decreased by 3.17% to -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then crashed by 52.71% to $40.4 million in 2024, then skyrocketed by 83.97% to $74.3 million in 2025.
- Its Cash from Operations stands at $74.3 million for Q3 2025, versus $64.0 million for Q2 2025 and $20.3 million for Q1 2025.